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Being in Control? A Thematic Content Analysis of 14 In-Depth Interviews with 2,4-
Dinitrophenol Users 
Abstract 
Background: 2,4-Dinitrophenol (2,4-DNP) is a compound with multiple industrial purposes. 
Currently unlicensed for human consumption, it is used by the gym-going population for 
drastic, short-term body fat loss. Nonetheless, physiological mechanisms can lead to 
potentially fatal hyperthermia. Reported fatal incidents have caused concern and highlighted 
the need for intervention. Understanding decision-making leading to 2,4-DNP use alongside 
the perceived outgroup attitudes is vital to forming effective harm minimisation policies 
targeting current and potential users. First-hand accounts from this elusive population are 
scarce. 
Methods: Fourteen novel and experienced users (13 male, 1 female) were recruited via 
“snowballing” techniques. Semi-structured interviews were conducted, comprising 28 
questions. Thematic content analysis was conducted using 37 codes. 
Results: Four characteristic themes emerged: 1. Users considered the Internet to be a 
crucial multifunctional resource directly impacting their 2,4-DNP use. 2. Users “respected” 
2,4-DNP, proactively taking harm reduction measures. 3. Attitudinal polarisation towards 2,4-
DNP within the gym-going community was consistent in all accounts. 4. Users perceived 
outgroup populations to have inherently negative attitudes towards their use. These themes 
fell under the all-encompassing theme of “being in control”. 
Conclusion: For the first time, this study offers a rich detail of attitudes toward 2,4-DNP use 
by giving a collective voice to users. The element of control over every aspect of the users’ 
life appears to be a significant contributor to the successful risk-management of 2,4-DNP 
use. In the absence of an established safe upper limit and effective regulatory control, 
education is critical to harm minimisation. 
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The use of performance enhancing drugs (PEDs) among bodybuilders around the 
world has been abundantly discussed in literature (Abrahin, de Sousa, & Santos, 2014; 
Perry, Lund, Deninger, Kutscher, & Schneider, 2005; Sepehri, Mousavi Fard, & Sepehri, 
2009; Nakhaee, Pakravan, & Nakhaee, 2013; Sagoe, Andreassen, & Pallesen, 2014). 
Based on self-reported surveys, prevalence rates for PED use among gym users ranges 
between 0.4% to 35% (Abrahin et al., 2014; Hitti, Melki, & Mufarrij, 2014; Khullar, Scull, 
Deeny, & Hamdan, 2016; Lazuras et al., 2017; Molero, Bakshi, & Gripenberg, 2017; Sagoe, 
Molde, Andreassen, Torsheim, & Pallesen, 2014; Simon, Striegel, Aust, Dietz, & Ulrich, 
2006; Striegel et al., 2006; Stubbe, Chorus, Frank, Hon, & Heijden, 2014). Within this range, 
PEDs prevalence figures vary widely across substance types, timeframe and methods used 
to establish prevalence. Specifically, much focus has been on anabolic steroid use. Direct 
questioning methods typically yield a lower and more likely prevalence rate compared to 
indirect methods. 
Uncertainty about the true prevalence rate aside, information concerning use 
patterns in this community is still limited, due to the attached societal stigma. The 
bodybuilding community appears to hide their substance use, and distorted perceptions are 
predominant in the general population (Evans, 2004; Gonzalez, McLachlan, & Keaney, 
2001). PEDs known to be generally used by bodybuilders are anabolic-androgenic steroids 
(AAS) (Kicman, 2008; Reardon & Creado, 2014; Sagoe, Molde, Andreassen, Torsheim, & 
Pallesen, 2014) and peptides such as human growth hormone (Meinhardt et al., 2010). Fat 
burners are also used, to create a larger caloric deficit for fat loss (Jeukendrup & Randell, 
2011), either through appetite suppression, direct effects upon users’ metabolism, or both. 
However, one compound that has flitted in and out of use is 2,4-dinitrophenol (2,4-DNP). 
Overview of the Compound 
2,4-DNP is a member of the dinitrophenol chemical family. These chemicals have a 
wide variety of industrial applications (Harris & Cocoran, 1995). 2,4-DNP raised interest 
upon discovering that ingestion caused significant weight loss (Harris & Cocoran, 1995) and 
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consequently, the compound was prescribed as a weight loss aid (Hardgrove & Stem, 1938; 
Harris & Cocoran, 1995; Horner, 1942; Parascandola, 1974). Between 1933 and 1935, an 
estimated 100,000 patients were given 2,4-DNP (Tainter, Stockton & Cutting, 1935). Studies 
concerning human oral exposure comprise primarily of case reports and clinical studies 
dating between 1932 and 1938 (Harris & Cocoran, 1995). These studies frequently had 
limitations as human trials did not include participant matched control groups (Harris & 
Cocoran, 1995). This has created difficulty in separating side effects caused by 2,4-DNP to 
potential pre-existing conditions of participants. Reliable accounts of 2,4-DNP’s effects on 
humans thus lack in current literature. 
2,4-DNP works through a variety of dose-dependent physiological mechanisms. 
Alongside being an uncoupler of oxidative phosphorylation, 2,4-DNP is also a chemical 
ionophore (Grundlingh, Dargan, El-Zanfaly, & Wood, 2011). The resulting proton 
electrochemical gradient shift from this process means this potential energy dissipates as 
excess heat, rather than ATP conversion (; Grundlingh et al., 2011; Wallace & Starkov, 
2000). At high doses, ingesting the compound results in an elevated body temperature 
alongside increased caloric expenditure, leading to fat loss. Possible side effects also 
include hyperthermia, tachycardia, skin discolouration or rash (if allergic), nausea or 
vomiting, abdominal pain, agitation and headache, excessive sweating potentially resulting 
in electrolyte imbalances (Kamour et al., 2015). Some studies have suggested long term 
risks relating to peripheral neuropathy (Phillips & Singer, 2013). Moreover, others have 
suggested the possibility of cataract formation from prolonged exposure (Allen & Benson, 
1935; Boardman, 1935; Kniskern, 1935; Lazar, 1935). However, mechanisms remain 
unclear and potential harms – apart from media reports of fatalities - are relatively unknown. 
In addition to the level of acute health risks, there is a distinct differentiation between 
2,4-DNP and AAS regarding effort. Because of its mechanism of action, 2,4-DNP use may 
appear as a shortcut for weight loss compared to dietary adherence. Notably, 2,4-DNP use 
has acute effect on lifestyle and wellbeing. Despite this, it is still considered less effort to use 
2,4-DNP compared to AAS. This will be discussed in further detail later on. 
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Currently, 2,4-DNP is not licensed for human consumption globally. No therapeutic 
dosage and duration, or safe upper limit, is established. Despite this, users are not 
dissuaded from using 2,4-DNP for fat burning purposes, and can easily access it from online 
sources. 
Method of Use 
The route of administration of 2,4-DNP is oral, taken either as tablets or capsules, 
once or twice a day. Based on users’ online accounts and self-reports, 2,4-DNP appears to 
be commonly used in cycles (McVeigh et al., 2016; McVeigh, Germaine, & Van Hout, 2016; 
Petróczi et al., 2015). Most 2,4-DNP cycles are brief − lasting anywhere from one to four 
weeks, but rarely longer (McVeigh et al., 2016). Typically, 2,4-DNP cycles are variable and 
dependent on a number of factors, both internal (i.e., bodyweight) and external (i.e., weather 
conditions). Users will often determine the ideal dosage solely through their bodyweight, not 
factoring in external determinants.  
Accessibility and Motives for Use  
Sale of 2,4-DNP for human consumption is presently illegal in the UK due to health 
concerns (“Warnings issued over deadly DNP ‘diet drug’, 2013; '“FSA action over DNP ‘fat 
burner substances”', 2013; “New warnings issued over deadly DNP ‘diet drug”', 2014). 
Consequently, users now take advantage of its easy accessibility via the Internet (McVeigh 
et al., 2016; Petróczi et al., 2015). An additional challenge is the ease with which 2,4-DNP 
can be obtained; as long as it is advertised “not to be used for human consumption”, 2,4-
DNP can be sold without limitations (Petróczi et al., 2015). Compounding the issue are 
discussion boards, which users utilise to seek guidance and share experiences (Barratt, 
2011). These factors counterbalance efforts of regulatory bodies to prevent access and use 
of 2,4-DNP. 
2,4-DNP appears to be utilised by the gym-going population owing to its unique 
muscle-sparing properties (Goldgof et al., 2014). The existing limited literature suggests that 
motives for using 2,4-DNP are primarily tied to the short-term aesthetic goal of losing 
considerable amounts of body fat (McVeigh et al., 2016; Petróczi et al., 2015). Similar 
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motives were found amongst young non-exerciser adults in hypothetical situations; those 
who wished to rapidly lose a considerable amount of weight were the most willing to take the 
risk with 2,4-DNP (Hoxha & Petróczi, 2015). 
Studies exploring prevalence and the experiences of users with regards to motives, 
reasons and risk perceptions associated with 2,4-DNP use are inadequate or non-existent. 
To date, research has evidenced that 2,4-DNP users make self-perceived conscious and 
informed decisions about 2,4-DNP and are well-prepared for the side effects (McVeigh et al., 
2016; Petróczi et al., 2015;). Willingness to take risks with 2,4-DNP has been linked to body 
image and magnitude of the desired weight or fat loss (Hoxha & Petróczi, 2015; Petróczi et 
al., 2015). However, studies investigating this matter are limited. There appears to be a clear 
gap in knowledge and disconnect between 2,4-DNP users and the scientific community 
researching voluntary 2,4-DNP use. 
 
 
Aims and Objectives 
Whilst prevention via warnings about the danger of 2,4-DNP could be an effective 
strategy for the naïve potential users, this approach is unlikely to deter those who are 
knowledgeable and experienced PED users. Prevention via controlling the supply has 
deemed difficult because of the widespread availability of the drug through the Internet. 
Where deterrence and control fail, there is room and need for strategies that primarily aims 
at harm-reduction. In order to explore 2,4-DNP use and implement harm reduction measures 
for this population, further evidence-based information is required. Though some 
understanding of the physiological effects of 2,4-DNP are evidenced through case reports 
and animal model experiments, very little is uncovered regarding psychological factors. Due 
to 2,4-DNP use being considered high risk and potentially dangerous behaviour even within 
the gym-going population, users tend to be very cautious when disclosing their 2,4-DNP use. 
As such, they are a hard-to-reach population, resulting in studies harvesting data from the 
Internet forums and discussion boards (e.g., McVeigh et al., 2016). 
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A better understanding of this population can be reached by examining attitudes and 
subjective experiences with 2,4-DNP of the users. This study, for the first time, set out to 
provide a more thorough and comprehensive qualitative overview of users’ experiences 
through thematic content analysis of semi-structured interviews. In particular, we aimed to 
explore 2,4-DNP users’ attitudes towards the Internet as a tool, perceived attitudes of in-
groups and out-groups towards their 2,4-DNP use, as well as exploring 2,4-DNP use through 
participants’ attitudes towards the compound. This, in turn, can inform practically relevant 
and meaningful harm-reduction policies which are accepted by this population. 
 
 
 
Methods 
Participant recruitment 
Recruitment consisted of a purposive sampling strategy carried out online. 
“Snowballing”, the recruitment of participants from a hidden population through peer referral 
(Biernacki & Waldorf, 1981) procedures were utilised. This involved making initial contact 
with “gatekeepers” of various bodybuilding forums discussing 2,4-DNP use to gain better 
access to potential participants. The researcher was active in these forums and familiarised 
with their administrators. Discussing the study with gatekeepers helped  credibility and made 
recruitment far easier than having approached individuals directly. Online recruiting from this 
population was challenging; the main reasons being the sensitive nature of discussing such 
compounds and a perceived lack of anonymity. 
Specific exclusion/inclusion criteria for participants were being over 18 years of age 
and having previously done, or were currently doing, a 2,4-DNP cycle. Credibility of 
participants’ accounts was individually judged by the level and accuracy of the specific 
details and information by which they described their experiences with 2,4-DNP (Gergen & 
Gergen, 2000). 
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Utmost care was taken to ensure participants’ confidentiality, and this was 
emphasised when discussing the details of the study. Self-assigned alphanumerical codes 
were used for transcription and data analysis to maintain confidentiality and anonymity. 
Ethical approval was granted for the project by the Research Ethics Committee of the 
Faculty of Science, Engineering and Computing, Kingston University. Informed consent, 
voluntary participation, confidentiality and right to withdraw at any time from the study were 
all discussed with participants pre-interview, alongside any other queries. 
 
Measures: semi-structured interviews 
Semi-structured interviews were employed. The interview consisted of 28 questions 
(Appendix A), which were created by the research team and explored motivations, reasons, 
expectations, side effects, use of other drugs, knowledge of 2,4-DNP, peers and purchase. 
Interviews were designed to facilitate adequate dialogue between the interviewer and 
participant. Capitalising on the researcher having an in-depth understanding of the 
environment and surrounding culture, open questions were used as much as possible. 
Where possible, the interviewer asked the participant to expand upon answers in order to 
gather more information. 
All interviews were conducted via Skype (v. 7.21.0.100 through to v.7.27.0.101) as 
participants resided in different parts of the world. Audio-only calls were used to ensure 
anonymity. Due to the stigmatisation of the compound even within gym communities, and its 
worldwide illegality concerning human consumption, we considered it prudent to utilise 
audio-only interviews. The locations of participants around the world meant that in person 
interviews were not possible. Interviews were recorded using a recording app (Audio 
Recorder, Android Open Source Project) on a smart phone (Samsung Galaxy S5) and 
uploaded to a password-protected computer. 
Data analysis:  
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Transcription was conducted by the researcher (NPA) with the aid of an online 
transcription application (https://transcribe.wreally.com/). All identifying information was 
redacted from transcripts. 
A thematic content analysis approach was employed to analyse the data (Braun & 
Clarke, 2006). Due to the nature of the study, a deductive approach was used. This 
approach fit the methodology best to form themes driven by our theoretical interests in the 
area. A closed coding scheme was utilised; codes were determined pre-hoc and revised with 
the research team during analysis. Coding was conducted individually, then compared with 
the group of researchers to ensure consistency (Weber, 1990). The finalised codebook 
consisted of 37 codes (Appendix B). Clearly defined definitions of each code were 
constructed, and every effort was made to ensure consistency during the coding process. 
Atlas.ti (v.7.1.50) software was used for coding and analysis. 
The process of theme formation was conducted by aggregating codes which we 
considered semantically similar, or which revolved around a similar facet present within the 
data.  Thematic formation was conducted through a number of ways; firstly, frequency 
counts were analysed to determine if any codes had a large count (grounded), or were 
connected to other codes.  Additionally, codes were pre-grouped into sub-themes before 
coding commenced.   These sub-themes were further organised into over-arching themes, 
which could be applied to our dataset as a whole (Braun & Clarke, 2006).   
The process of thematic analysis (Braun & Clarke, 2006) was organized in a clear 
framework that assisted researchers during the analytical step of this study.  Throughout the 
process, in order to maintain the flexibility afforded by this methodology, codes were revised 
where necessary.  This included post-hoc codification of text segments.  Constantly 
checking over data, and recoding and rechecking the transcripts enabled the researchers to 
increase reliability of the codebook.   
Results 
Participant sample demographics 
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The final sample for the semi-structured interviews consisted of 14 participants (13 
males and 1 female). The median age was 22 years old (age range of 19–39 years old). All 
but one participant were aged below 30 years old, with the remaining participant being over 
30 years old. Self-reported ethnic origin breakdowns were as follows: 10 were 
White/Caucasian, one was Asian (Oriental), one was Asian (Indian, Pakistani, or 
Bangladeshi), one was Hispanic or Latino and one was mixed. With regards to locality, 11 
resided in the USA, one in Canada, one in Germany and one in the Netherlands. All 
participants considered themselves regular gym goers. 
Thirteen participants had used some form of PED or were currently using PEDs, with 
the remaining participant having no history of other PED use. Most participants had used 
recreational drugs previously (such as alcohol or marijuana). During their 2,4-DNP cycles, 
only one drank alcohol and two used marijuana. The rest did not use recreational drugs on 
cycle. Nine participants concurrently used other PEDs on their 2,4-DNP cycles. Participants’ 
accounts regarding side effects and dosages were consistent with other reports of 2,4-DNP 
use.  
Emerging themes 
Thematic analysis revealed four core themes: (1) attitudes towards the Internet as a 
tool (“The world at your fingertips”), (2) non-participant societal and close peer group 
attitudes towards 2,4-DNP use (“What they would know about the horror stories”), (3) 
attitudes of the gym-going community (“There’s two extremes…”) and (4) participant 
attitudes towards 2,4-DNP (“I have to respect the hell out of this supplement”). These four 
core themes are related to each other through varying degrees, encapsulated in the 
overarching theme of “being in control” (as shown in Figure 1) and are vital in understanding 
2,4-DNP users’ experiences. The following sections are organised into the aforementioned 
overarching themes and further described through key concepts which emerged from 
analysis. 
 
[INSERT FIGURE 1 HERE] 
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Attitudes towards the internet as a tool (“The world at your fingertips…”) 
For our group of participants, the Internet was a vital tool. Not only did our 
participants have access to the vast array of information related to 2,4-DNP, they were also 
able to share experiences with other peers using the drug. By bringing such a variety of 
shared experiences and knowledge sources, one participant described it as “the world at 
your fingertips” (Male, the Netherlands). 
The secrecy within these communities can make it difficult to obtain information and 
even 2,4-DNP sources. However, some participants had doubts regarding advice given over 
the Internet: 
“…you're getting all this information not from a medical doctor, you know, from a bunch of 
dudes on the internet. And as much as it sounded like enough people have used it and put 
in the time and collectively pooled their experiences and stories that gave me a good base, 
it's still always a thought in the back of my mind because you know, I don't know how my 
body personally will respond to this, even though I'm just taking the one dose, I have no 
idea…” (Male, USA). 
This excerpt hints at the risk present not only through ingesting 2,4-DNP, but also 
through taking advice from this online community. The wide accessibility of the Internet 
meant anyone could potentially offer advice, whether it is correct and safe or not. Some 
participants consequently had to be careful sifting the “broscience” (commonly accepted 
term in the community for non-scientifically based information) from the science; 
“One thing I had to learn to do not just with DNP but with uh, steroids as well is to filter the 
information and take everything with a grain of salt to learn what is considered I guess you 
can say broscience or you know, things that people discuss and not really have scientific 
backing for? versus reliable anecdotal evidence just because there isn't too much scientific 
evidence on a lot of these products that we're using. So lots and lots of research and lots 
and lots of digging through mud I guess you could say, to make sure that the information I 
had was more or less reliable.” (Male, Canada). 
RUNNING HEAD: QUALITATIVE ENQUIRY OF 2,4-DINITROPHENOL USE 
 
11 
 
In short, our participants acknowledged the power of the Internet as a rich source of 
information. There was awareness that getting information from anonymous sources on the 
Internet was risky, and consequently participants were cautious when using it. Peer 
experiences were considered vital, despite the need for careful interpretation. 
Perceptions of societal and close peer group attitudes towards 2,4-DNP use (“What 
they would know about the horror stories”) 
Within this section, participants’ perceptions of society, friends and family’s attitudes 
towards 2,4-DNP use are discussed separately. An important distinction between personal 
attitudes and outgroup’s attitudes emerged strongly from the interviews. Both society’s and 
social groups’ attitudes towards 2,4-DNP were thought to be shaped by media reports of 
fatal cases. A further differentiation within friends dependent on their inclusion or exclusion 
from the gym-going community was also evident. 
 
 
Perceived perceptions of society towards 2,4-DNP use 
In 2015, there was notable international media attention for the death of a young 
woman from a 2,4-DNP overdose (Morris, 2015). Many participants thought it to have had a 
significant impact on 2,4-DNP use perception by non-PED using outgroups; 
“I imagine the average person we'd run into on the street, if they knew about DNP at 
all, what they would know about is the horror stories that, you know, come on the new… 
And, you know, their judgement of me using DNP would then be based on that, you know, 
very, very biased, very case-specific um, information.” (Male, the Netherlands). 
The use of the word “biased” implies that the public has a one-sided opinion, and this 
was a viewpoint shared by the whole cohort. When explaining why outgroups would consider 
2,4-DNP negatively, participants commented on “laypeople” relying on news reports and 
superficial information; 
“…you know, people fear what they don't understand and you know, perhaps 
rightfully so. But if people would do a little bit of research, before they give their opinions, I 
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think we wouldn't have as much of an issue with it… I think the lack of education about DNP 
um, and all the other PEDs just causes issues you know. If people know how it worked, 
there wouldn't be a huge issue with it. It would just be, ‘let's make sure you do it safely'. But 
you know, that's not how it is right now.” (Male, USA). 
Interestingly enough, some participants thought this negative viewpoint to be 
beneficial; “the last thing we need is more people that have no idea what they're doing, 
getting a hold of it and killing themselves with it. It's a dangerous compound, you know.” 
(Male, USA). Several participants drew parallels between 2,4-DNP use and AAS use, saying 
2,4-DNP use has a “very similar vibe as steroids have, where you hear about only the bad 
things that can happen and you never look at all the benefits.” (Male, USA). AAS use is often 
associated with an aesthetic extreme of large amounts of muscle mass and consequently 
seen as an aesthetic outlier. 
When discussing whether this attitude would change in the future, one participant 
was optimistic regarding future perceptions of 2,4-DNP: “I think at least, based on America, 
[laughs], everyone here is looking for that magic skinny pill that helps you lose weight…” 
(Male, USA). Weight loss is a relatable goal for the majority of the general public, as it fits 
with the “traditional” societal norms of beauty, particularly in Western societies.  
The idea of an uninformed public is clear through these excerpts; the public is 
perceived as having “no idea” regarding what they are doing, alongside making hasty 
judgements based on a prominent media story. An ingroup/outgroup divide emerges from 
the data. This could account for the secrecy which surrounds the community, and could 
impact help-seeking behaviours. 
Perceived attitudes of friends and protecting self-image 
In general, participants were hesitant to inform their social networks of their 2,4-DNP 
cycles. It was perceived that naïve individuals held biased views towards this practice and 
only ingroup members could have an informed and valid opinion. 
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Participants sometimes divided their friend groups into “bodybuilding friends” and 
“non-bodybuilding friends”. This was crucial in their eyes; related to the earlier concept of the 
“layperson’s” lack of education and misconceptions. One participant said “…didn't want them 
to uh, think that I was some crazy drug addict either because if my friends outside the 
bodybuilding community heard that I was using this performance enhancing drug, I think 
their initial reaction would be ‘oh my gosh you are doing drugs, that's bad' and I did not want 
them to think that at all.” (Female, USA). Fundamentally, participants viewed only ingroup 
gym-goers as trustworthy in relation to the accuracy of their opinions of 2,4-DNP. They were 
very concerned of outgroup’s prejudices and negative opinions of drug use, and how they 
could potentially be damaged by negative stereotypes. 
Protecting the family 
The decision whether to tell friends and family about drug use can be difficult. Our 
cohort feared closure and non-acceptance, particularly with family. Those who kept their use 
away from family had various justifications for not informing them of their 2,4-DNP use, with 
one stating “what they don't know won't hurt them.” (Female, USA). One participant 
elaborates on his decision to tell some of his friends and family: 
“I'm pretty open about my PED use so it was something that, um, most of my friends 
were kind of interested in when they found out. You know, I have done a good job of 
explaining stuff to people so um, I didn't have any problem telling most of them. I kept it on 
the down low for the most part cos of… my parents, cos they weren't huge fans of it. But 
everyone else I was pretty open with. And, um, you know, it was a good experience from 
that too, I had other people that'd, you know, if something were to go wrong, they would 
know about it at least…it wouldn't be a whole bunch of people wondering what happened.” 
(Male, USA). 
This particular individual’s reasoning for informing his friends and family stemmed 
partly from a safety perspective. The usage of the word “at least” indicates that this was a 
minimum requirement for them, made on a personal level. Informing a small group of people 
for safety reasons was suggested as good practice. 
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Perceived attitudes of the gym-going community (“There’s two extremes…”) 
Participants almost universally acknowledged that there was growing interest within 
the gym-going community for 2,4-DNP use; some individuals were more “open” to its use, 
whilst others considered it to be wholly dangerous and unnecessary to any fat-loss goals 
individuals might have: 
“… as with many things, there's two extremes: people who are very much for it you 
know, who supported using and people who you know, call it ‘The Devil' and say no, you 
should never use it. And there's people in between…” (Male, the Netherlands). 
Some participants offered potential reasons why some individuals in the gym-going 
population might disapprove of 2,4-DNP use; “…a lot of people don't like that there is this pill 
that you can take which causes you to lose fat” (Male, Canada). These people believe that 
there is an extremely high possibility of abuse. 2,4-DNP is viewed negatively because it is 
seen as a “no effort” pathway to reaching weight loss goals. 2,4-DNP is considered different 
to other PEDs: with other PEDs, the general understanding is that you still have to work hard 
and be consistent, whereas with 2,4-DNP, “you take it and it works” (Male, Canada), 
implying training and diet are not needed. 
Participant attitudes towards 2,4-DNP (“I have to respect the hell out of this 
supplement”) 
Our participants were almost overwhelmingly positive about their use of 2,4-DNP, 
although they emphasised the need to “respect” the compound due to the potential adverse 
effects, alongside its lethality at certain doses; 
“Right, my opinion is that it can be used very safely, and very effectively, to get great 
results, in a short period of time. But, the other side of the coin that, the other side of the coin 
is, you know, this is a fact, is that it is lethal at a certain dosage you know. There is all these 
adverse effects you know, such as the cataracts, it messing with you, with your thyroids, 
your metabolism, all these different things. It can adversely affect you that way. I think if you 
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know what you're doing, and you do it properly, it can be used very safely and very 
effectively.” (Male, the Netherlands). 
For other participants, similar themes of respect and “doing it properly” were notable. 
it is crucial that underlying attitudes towards 2,4-DNP are “… based on the foundation of ‘I 
have to respect the hell out of this supplement’ and I can't ever get out of turning into this 
mindset of getting impatient or taking more is better.” (Male, USA). 
According to another participant, the “wrong way” can lead to consequences “as 
severe as, you know, death. Or you know, having to deal with PN [peripheral neuropathy] 
symptoms for a long time or developing cataracts” if you do it the “wrong way”. (Male, USA) 
Most acknowledged that high doses were dangerous and condemned individuals 
taking high risks; 
“…they're running a gram a day and I think that's reckless and asking for something 
to go terribly wrong. I believe the half-life is somewhere around 36 h, so I mean there's no 
way to get it out of your body other than waiting. And if you gotta wait 36 h for half of it to get 
metabolised, there's nothing you're gonna be able to do to keep yourself alive and your body 
just starts cooking…” (Male, USA). 
Upon further elaboration, when asked if they would ever push the boundaries with 
dosages, almost every participant said no. One went so far as to state that “it'd be a… one 
time experience thing [laughs]…” (Male, USA). Another stated: 
 
“Not in a million years. For me…there's really no need, why risk messing up my 
body, you know. It's a marathon, not a sprint.” (Male, USA). 
In contrast, our participants strongly advocated for harm reduction measures as 
being the “right way” to approach using 2,4-DNP. One participant stated the importance of 
implementing “…due diligence and background, getting the blood work you need, taking the 
supplements and cycle support you need.” (Male, USA).  
When asked if they would recommend 2,4-DNP to anyone else, there was a definite 
polarisation. Some stated they would recommend it, provided certain conditions were met 
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“I would definitely recommend DNP to people given that I have sufficient background 
with them. Erm, for someone for example online as I do most of my discussions online, I 
would not recommend it freely just because, I would give my opinion on it but I wouldn't 
actually tell them whether or not they should do it.” (Male, Canada). 
However, others went so far in the other direction; 
“I would not recommend DNP to my worst enemy. It is, in my mind, it is a poison as 
well, I take it because I want the results. I do, if somebody told me they were taking it, as 
long as they've done their research, I will wholeheartedly support them. But I would never 
recommend it to somebody. I'd rather them find out about it on their own, do their own 
research and fully understand and grasp what DNP can do, what potential side effects are, 
what you can really gain from it before attempting it. And I would never, I would never supply 
it to anybody, I would never recommend it.” (Male, USA). 
Our cohort considered themselves to have a strong respect for the compounds, 
grown out of the research they had conducted before using 2,4-DNP. Most participants 
strongly advocated for individual research before embarking on a 2,4-DNP cycle and 
implementation of harm reduction measures. Polarised attitudes towards recommending 2,4-
DNP could be, in part, due to its lethality and severity of potential adverse effects. 
Discussion 
Our results give a number of novel insights regarding how 2,4-DNP users approach 
their use, as well as how perceived public perceptions influence their behaviour. It is clear 
that the majority of users get their information almost exclusively from the Internet. Users 
consider themselves well-educated on the risks and effects of 2,4-DNP, with most having 
done what they considered to be extensive research before embarking upon a cycle. 
The four themes can be viewed through the overarching thematic lens of control, 
present to some degree in all the sub-themes discussed. It was clear how important the 
Internet was with regards to users’ 2,4-DNP experiences. Users turned to the Internet for a 
number of purposes; from sourcing 2,4-DNP, to researching the compound and cycle 
details, as well as peer-to-peer experience sharing. In this sense, it was considered a 
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powerful tool that allowed the sample to exert control over this risky practice. In particular, 
the Internet enabled users to exhibit greater control over their 2,4-DNP experiences in the 
following ways: 
Firstly, the anonymity the Internet can provide was considered a valuable asset. 
Users can choose to be as anonymous or identifiable as they wished. There are a number of 
methods used to research and obtain 2,4-DNP which leave no trace. With regards to PEDs 
in general and the stigma attached to them, anonymity is extremely important for users. 
Many stated they did not want friends or family to know, due to the surrounding negative 
attitudes. 
Secondly, the wide variety of PED-related information available via the Internet 
makes it a powerful tool for research. For example, several participants were able to find 
research papers about 2,4-DNP use effects on humans, increasing their knowledge on the 
compound’s effects. Additionally, users could get anecdotal information from specific forums. 
Users were able to control which of these sources of information they utilised, based on their 
level of knowledge and trust in the information source. 
Thirdly, participants had a wide variety of suppliers and vendors from which to 
choose. Different suppliers provide different dosages per capsule, types of 2,4-DNP 
(whether it was crystal or powder form), and even possibly supply other PEDs for 
participants. 
Users’ attitudes towards public perception of 2,4-DNP influenced who they told about 
their use. Many users made the conscious decision to not divulge their drug use to their 
family (and often friends). Some made the distinction between “gym going” friends and “non 
gym-going friends”. The stigma attached to 2,4-DNP use has many similarities to 
stereotypes associated to the use of PEDs in general. Some participants likened it to the 
overwhelmingly negative attitudes prevalent in society towards AAS use. Notably, some 
participants perceived this negative stigma as a benefit, in order to prevent any “laypeople” 
encountering and ingesting the drug. Most participants in this sample had experience with 
previous PED use, therefore considering themselves well-versed in harm reduction in similar 
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contexts. In contrast, the general population was not as well educated or knowledgeable 
about the necessary harm reduction measures necessary with any PED. Participants made 
it clear they were different from the general public due to their knowledge and experience 
with PEDs, as well as training and diet. 
An additional point to consider is the distinction even within the gym-going 
community between 2,4-DNP and other PEDs regarding effort. The use of 2,4-DNP has 
been reported to increase basal metabolic rate by 11% for every 100 mg ingested 
(Grundlingh et al., 2011). The gym-going community considers 2,4-DNP a “short cut” 
compared to other methods of losing weight, since a rigid diet is not necessary for the drug 
to be effective. Conversely, AAS use is associated with pushing beyond genetic “natural” 
limits, a perceived necessity for certain disciplines such as bodybuilding. 
Finally, the control theme underpins all aspects pertaining actual 2,4-DNP use. 
Participants controlled their lifestyle and other substance use while on 2,4-DNP and all but 
one benefitted from having experience with other PEDs. Users in this study also carefully 
controlled what, when and how much they revealed about their high-risk behaviour to their 
social groups and differentiated based on how well-informed they believed they were. Users 
also considered their social image when choosing not to tell friends about 2,4-DNP use. This 
high degree of control, coupled with respect for this very potent but highly toxic chemical 
suggests very clearly that users do not haphazardly take risks with 2,4-DNP. Rather, users 
search for information, educate themselves about the drugs and side effects, keeping a 
controlled lifestyle and not exceeding the amount they felt was “safe”. 
Participants were well aware of the risks associated to 2,4-DNP use. Many 
participants had a “threshold” dose which they would not bypass due to their concern about 
unwanted side effects. In particular, participants were concerned about death. Whilst 
participants seemed keen to take the risk of ingesting 2,4-DNP, the risk appears to be a 
“calculated” one, rather than an impulsive decision. 
What is clear from the interviews is that participants would take as many measures 
as they felt were necessary to mitigate negative effects and yield only positive outcomes 
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from 2,4-DNP use. According to the sample, negative societal effects (by not informing 
certain social groups of their use and maintaining anonymity) and negative physical effects 
(through the use of supplements or drugs, as well as through self-experimentation) could be 
contained and controlled. For participants, controlling and mitigating negative effects was 
crucial and each participant exercised their control by making certain choices within their 
goals and possibilities. 
It can be suggested that the control element found in our cohort’s narrations reflects 
commonalities with eating disorder symptomatology (Marzano-Parisoli, 2001). A distinction 
between “practical” control (in this context, controlling as many elements as possible to 
reduce harm from the compound) and “pathological” control (control which stems from a 
pathological root) is nonetheless necessary. Media reports indicate that in those suffering 
from eating disorders or some other pathological conditions (e.g., exercise addiction) and 
use 2,4-DNP, often fatally (e.g., Moore, 2017 July 27; Philby, 2013, April 23), death or 
serious health conditions were related to overdosing with 2,4-DNP. It remains unknown 
whether overdosing were due to impurity; the lack of knowledge and understanding or loss 
of control over the measures taken for weight loss. Further research is warranted to compare 
and contrast elements of “practical” control, necessary when using a highly lethal compound 
such as 2,4-DNP and the “pathological” control characteristic of eating disorders or exercise 
addiction. 
Comparisons with past research   
In part due to difficulties in recruiting from this population group, studies on attitudes 
of 2,4-DNP users have been scarce. Qualitative studies which include thematic analysis are 
even rarer. Petróczi et al. (2015) administered a semi-qualitative, self-reported survey to 35 
2,4-DNP users. Similar to our results, the Internet was a major source for obtaining 
information on 2,4-DNP as well as for acquiring the actual substance. Users were aware of 
the health risks and made an informed choice to use the compound regardless. 
A netnographic study was undertaken by McVeigh et al. (2016). This study examined 
online community comments from 2,4-DNP users, using thematic analysis. The results 
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uncovered novel descriptive information focused on purchasing, dosages, outcomes, side 
effects and cycles. Individuals’ attitudes towards 2,4-DNP partly mirrored our results; user 
groups utilised scientific studies and discussed use from a physiological perspective. Whilst 
McVeigh et al. (2016) compared 2,4-DNP users to novel psychoactive substance (NPS) 
users, we identified differences between 2,4-DNP users and AAS users. 
Fimognari and Gottardi (2010) suggested a spectrum of two extremes of AAS users; 
the ‘first extreme profile’ is an individual who has a high hazard knowledge and correct risk 
perception − though the perceived high reward is worth the risk in their eyes. The second 
user is the ‘second extreme profile’, an individual who perceives a moderate amount of 
reward, yet risk and hazard perception related to AAS are limited. Fimognari &and Gottardi 
(2010) suggested most users will fall between these two extremes. It is possible to extend 
this scale to 2,4-DNP users − the majority of our participants acknowledge the high risk and 
numerous potential hazards associated with using the substance. However, the high reward 
(high amount of fat loss in a short amount of time) is worth the calculated decision they 
made. Thus it is possible they would fall under the “first extreme profile”. 
This is also reflected in the amount of 2,4-DNP users ingest. In our and similar 
studies, 2,4-DNP users appear to be significantly more conservative with their doses when 
compared to AAS users. Parkinson and Evans (2006) found that the average dose of AAS 
used has increased from 1997 (where the reported dosage was 500 mg) to 2006 (where 
dosages of 1000 mg and more were reported in the study). Whilst no studies exist to 
determine typical 2,4-DNP dosage, informal suggestions range between 200 and 600 mg, 
with potential users being advised to start off at the lower end and gradually taper up if they 
can do so (Petróczi et al., 2015). AAS users are mostly concerned about long term effects 
(Parkinson & Evans, 2006), and side effect increases with increasing doses and number of 
AAS taken concurrently (Bolding, Sherr, & Elford, 2002). Long term risks versus short term 
risks could potentially influence the risk and hazard perception of each user group, and this 
perception of acute harm could impact the dosages and methods of use in AAS compared to 
2,4-DNP. 
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Limitations and future directions  
Procedural limitations were present within this study. One of the main limitations was 
sample size. Despite the interviewer being an “insider” for the community, recruitment was 
still challenging due to the high level of suspicion among community members. Additionally, 
recruitment was conducted in a short period of time (approximately four weeks). It is possible 
that a larger sample could be recruited over a longer period. However, it should be noted 
that a sufficient level of data saturation (Fusch & Ness, 2015) was reached with our sample; 
similar themes were appearing repeatedly, and a point had been reached where no novel 
information was appearing. 
Self-selection bias is an element present within this study. Many of the users in our 
sample were open about their drug use, as well as educated on it to some degree. However, 
providing representative information of 2,4-DNP users was not our intent. We aimed to 
provide an in-depth description of the 2,4-DNP decision-making processes. Future studies 
could perhaps recruit from gyms as well as other online avenues to diversify study 
populations, thereby opening up a new pool of participants who could discuss a different 
array of attitudes and experiences. 
Whilst we attempted to recruit from a diverse range of participants, it is clear most 
participants were white Caucasian males. This might be due to the stigmatisation of female 
PED use; female drug use in general appears more stigmatised than male drug use 
(Hecksher & Hesse, 2009; Van Olphen et al., 2009). Fewer women are willing to be open 
about their PED use compared to males. Scientific understanding of female PED use is 
much more limited compared to male PED use. Future research could potentially investigate 
female-specific 2,4-DNP use and decision-making. 
Recommendations for prevention and harm reduction policies 
It has been previously suggested in the context of AAS use that deterring people via 
exaggerated scare tactics and only emphasising negative effects has limited effectiveness 
(Petróczi, Dodge, Backhouse, & Adesanwo, 2014). Rather, an evidence-based harm 
reduction approach appears to be more effective in reducing health costs (Goldberg, Bents, 
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Bosworth, Trevisan, & Elliot, 1991). Another potential direction for future research would be 
gathering more participants from a wider cultural pool. Currently there is little research to 
determine whether cultural background influences how individuals approach PED use (in 
particular, fat burners such as 2,4-DNP). This could be accomplished via cross-country 
research. 
Prevention of use by presenting evidence-based information could be effective for 
non-users interested in initiating 2,4-DNP use. However, additional approaches should be 
considered for experienced 2,4-DNP users, who might not be so easily dissuaded from use. 
Additionally, the easy availability of the substance through the Internet makes “harm-
minimising” by controlling substance access challenging. It has been suggested that harm 
reduction in this context should focus on decreasing drug-related harm, as opposed to 
reducing drug use (Hunt et al., 2003). In the context of other PED users, this is a well-
established concept, for example through the use of needle and syringe service providers 
(NSPs). Notably, NSP programmes also provide information on maximising the effects 
obtained from AAS in order to minimise the amount used (Kimergård & McVeigh, 2014). 
In the past, AAS users have been reluctant to take advice from doctors as they feel 
they are more educated on AAS and other PEDs than health professionals (Pope, 
Kanayama, Ionescu-Pioggia, & Hudson, 2004). Future research could examine if similar 
processes occur in a representative 2,4-DNP user cohort, determining whether similar 
perceptions towards medical professionals are present. Considering the findings of this 
study, 2,4-DNP users are pro-actively engaged in avoiding potential harms but engage in 
preventative measures in an isolated manner. This protective factor can be reinforced and 
supported by acting on possible negative attitudes towards health professionals. 
Health professionals and other groups of people in contact with 2,4-DNP users 
should also understand that this population considers itself well informed about the risks 
involved. Our cohort utilised scientific studies (where possible) in order to determine 
dosages and educate themselves on side effects. It must also be remembered that this user 
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group bases decision-making on other users’ experiences, and realises that experimenting 
with such a substance without adequate medical supervision is inherently extremely risky. 
Findings also highlight the importance of creating and maintaining community 
relations with the target population; the depth and richness of information gathered during 
our qualitative interviews brought forth many valid harm reduction recommendations from 
our cohort, for example informing a close friend when starting a 2,4-DNP cycle. Additionally, 
it can be empowering for the community to be part of policy creation. It is imperative to forge 
a connection with the PED-using community, and actively involve them in policy creation as 
much as possible. Considering the submersed nature of the PED using population and the 
high risks involved in using 2,4-DNP, developing effective communication strategies that 
better inform research, policy and preventative measures is vital. Harm reduction is an 
important standpoint in promoting a non-judgemental attitude and improving communication 
with the PED using population (DeCorte, 2001). 
In a community where peer experiences are highly valued, peer-to-peer education 
schemes, presenting information in a non-judgemental light, and advocating the benefits of 
moderation in consumption whilst cautioning against excess could have beneficial outcomes 
for the gym-going population. Considering the dose-dependent danger associated with 2,4-
DNP, this moderation-based approach would be far more effective than withholding 
information to prevent use. Taking all of this into account, policy creation could potentially 
occur through well-conducted participant action research (PARs) initiatives (Baum, 
MacDougall, & Smith, 2006). 
 
Conclusion 
Participants concluded that if used with caution, 2,4-DNP is highly effective and 
efficient as a fat loss agent. However, many also remarked upon its dangers. The main 
concern, in addition to adverse physical effects, was the risk of death. Most considered 
“respect” for the compound to be important and pivotal to reduce adversities. Internet has a 
powerful role and interactions with peer groups online shaped perceptions towards 2,4-DNP 
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and other PEDs. Attitudes towards 2,4-DNP use are particularly polarised and complex 
within in-groups. 
Further research on 2,4-DNP use within gym-goers is warranted. Understanding 
users’ motives and decision-making processes is crucial to develop better interventions and 
policies. It is also a priority to adopt a non-judgemental approach and avoid further 
marginalisation of 2,4-DNP users. Instead, using their experiences to devise prevention, 
education and valid harm-reduction strategies could be beneficial to public health initiatives. 
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Figure 1. Visual presentation of emergent themes within this study 
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APPENDICES 
Appendix 1: Interview guide 
Thank you for taking part in this study. I am going to ask you some questions regarding your 
experience with DNP. I will audio record your answers. My research group is interested in 
understanding why people use DNP and finding out how we can protect your health and wellbeing 
and minimize harm. I value your experience and will not judge you in any way. I also guarantee 
complete confidentiality. Any private information you provide (names, places, etc.) will be deleted 
from the transcription. The information we gather may be used to produce a scientific paper. Parts 
of your answers may be used as examples within the manuscript. I want to clarify though that the 
information we gather will be interpreted as a whole and we are not interested in analysing you 
individually. We guarantee that your identity will be kept completely anonymous and will be 
safeguarded. Please confirm that you consent. 
 
1. When did you start training and what were your reason[s] for starting?' 'Do those reasons 
still motivate you to train or have your goals changed? 
 
2. What PED do you currently use? 
 
3. When did you start using PEDs? What were your reasons for doing so? 
 
4. How did you get to know about DNP? 
 
5. Where did you learn how to use it? 
 
6. What was the main reason you started using DNP? 
 
7. Can you describe the first time you used DNP? 
 
8. Have you had any previous experience with any other appearance enhancing drugs? 
 
9. Were you concerned about any repercussions that could have risen? 
 
10. How did you assure that the pills were actually DNP? 
 
11. Were you aware of the other uses of DNP? 
 
12. What did you want to gain from DNP? 
 
13. What was the purpose of adding DNP as a supplement to your regime? 
 
14. How did DNP change your physique? 
 
15. How did you plan your DNP cycles? 
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16. Can you describe the side effects arising from the beginning, during and after of the DNP 
cycle?  
 
17. When did side effects first appear? 
 
18. Have you researched about any of DNP side effects? 
 
19. Were there any changes in your mode of consumption since you started using DNP? 
 
20. Were you using any other recreational drugs, steroids or supplements while on DNP? 
 
21. How did you get a hold of DNP? 
 
22. How much would an average DNP cycle cost?  
 
23. Can you describe what the intake limit of your body is? 
 
24. How does your bodybuilding community react towards you using DNP?  
 
25. What do untrained people think about you using DNP? 
 
26. Were friends and family aware of your use of DNP? 
 
27. What is your opinion towards DNP?  (Have/would you recommend it to anybody?) 
 
28. What misconception have you found that people have about DNP? 
 
*Remember to keep the discussion as open as possible. Don’t be afraid to ask many “whys”. 
  
Variables 
Motivation  
Reasons 
Expectation 
Side effects  
Effects  
Use of other drugs 
Knowledge of DNP 
Peers 
Purchase 
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Appendix 2: Codebook for coding of transcripts  
 Motivations 
“Reasons for using DNP; my personal motivations” 
1. Losing weight 
2. To compete 
3. “other” motivations 
 
4. Expectations of positive effects (pros) 
“Pre-conceived notions regarding the advantages of using DNP; information from external 
sources” 
 
5. Expectations of negative effects (cons) 
“Pre-conceived notions regarding the disadvantages of using DNP; information from external 
sources” 
 
 Side-effects 
“Detrimental effects of DNP” 
6. Physiological side-effects 
7. Mental side-effects 
8. Impact on daily life 
 
 Duration of side-effects (of DNP use) 
9. Side-effects at the beginning 
10. Side-effects during 
11. Side-effects after 
 
 Effects 
“Positive outcomes related to DNP use” 
12. Aesthetic  effects 
13. Losing weight 
 
 DNP cycle details (to analyse post-hoc the “deviations from plan”) 
14. Type used 
15. Type of training 
16. Type of diet 
17. Time of day 
18. Duration of cycle 
19. Dosage 
 
 Use of other drugs besides DNP 
20. Drugs to have fun 
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21. Drugs to help daily function 
22. Other PEDs 
 
23. Other uses of DNP 
“Anything that does 
n’t involve fat burning” 
24. Sources of information 
 
 Attitudes of social networks 
“Opinions of DNP use on the part of family, friends and community” 
25. Views of the gym goers community 
26. Opinions of friends/family 
27. Attitudes of society 
28. Misconceptions of society 
 
29. Opinions towards DNP 
“Personal opinion after experiencing DNP” 
 
30. Would you recommend it? 
 
 Purchasing DNP 
“Information related to buying DNP” 
31. Cost of DNP 
32. Purchase from internet 
33. Purchase in person 
34. Accessibility 
35. Trust in the product 
 
 General Information 
“Athletic history of participants” 
36. Current training 
37. Athletic background 
 
